Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

— Company expects to present preliminary data from iMMagine-1 study in 2H’24 — REDWOOD CITY, Calif., Aug. 14, 2023 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with…

Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks